• MeSH
• krvácení diagnostické zobrazování   etiologie   MeSH
• lidé MeSH
• nemoci sedacího nervu etiologie   diagnostické zobrazování   diagnóza   MeSH
• nervus ischiadicus * diagnostické zobrazování   MeSH
• ultrasonografie metody   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• dopisy MeSH
• kazuistiky MeSH

• Publikační typ
• abstrakt z konference MeSH

Kazuistika přibližuje terminální fázi onemocnění pacientky s refrakterní neuropatickou bolestí způsobenou invazí karcinomu prsu do plexus brachialis. Chceme připomenout, že neuropatická nádorová bolest může být velmi těžko ovlivnitelná i za použití mnoha farmakologických i nefarmakologických postupů. Refrakterní bolest je nespornou indikací k paliativní sedaci, náročné může být správné načasování a vedení přiměřené hloubky sedace.

his case report presents the terminal phase of a patient with refractory neuropathic pain caused by invasion of breast cancer into the plexus brachialis. We want to remind that neuropathic cancer pain can be very difficult to control even with the use of many pharmacological and non-pharmacological approaches Refractory pain is an indisputable indication for palliative sedation; the correct timing and management of adequate depth of sedation can be challenging.

Background/Objectives: This retrospective study analyzed soluble urokinase plasminogen activator receptor (suPAR) plasma levels alongside routine inflammatory markers, including the neutrophil-to-lymphocyte count ratio, C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), and D-dimers in COVID-19 patients hospitalized during the Omicron wave of the pandemic. Methods: We measured plasma suPAR levels using a suPARnostic® Quick Triage kit. We divided COVID-19 patients into two groups based on the severity of SARS-CoV-2 infection according to the National Institutes of Health (NIH) criteria. The logistic regression analysis tested the predictive value of the biomarkers. Results: We evaluated 160 consecutive COVID-19 patients hospitalized between January and August 2022. The cohort exhibited a high incidence of comorbidities, with an in-hospital mortality rate of 5.6%. Upon admission, the median suPAR plasma levels were not significantly different between patients with mild COVID-19 (n = 110) and those with moderate/severe disease (n = 50), with 7.25 ng/mL and 7.55 ng/mL, respectively. We observed significant differences (p < 0.01) between the groups for CRP and IL-6 levels that were higher in moderate/severe disease than in mild infection. Additionally, suPAR plasma levels were above the normal range (0-2.00 ng/mL) in all patients, with a significant positive correlation identified between suPAR levels and serum IL-6, PCT, and creatinine levels. Conclusions: These findings indicate that COVID-19 during the Omicron wave is strongly associated with elevated suPAR levels; however, these levels do not directly correlate with the severity of SARS-CoV-2 infection.

• Publikační typ
• časopisecké články MeSH